Malignant Glioma Therapeutics Market, By Treatment (Chemotherapy, Radiation Therapy, Surgery, Targeted Therapy (Bevacizumab) and Tumor Treating Field (TTF) Therapy), By Drug Class, By End Use, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
ANV6006
|
Published Date
September 2026
|
Pages
322
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Malignant Glioma Therapeutics market size was valued at US$ 2,005.1 Million in 2025, expanding at a CAGR of 10.8% from 2026 to 2033.
Malignant glioma therapeutics involve a combined approach for the treatment of these aggressive brain tumors, involving surgical removal, radiation therapy, and chemotherapeutic treatment to increase survival rates and maintain neurological functions. The general paradigm is sequential max safe debulking resection, concurrent chemoradiation using temozolomide, adjuvant maintenance chemotherapy, and, in certain cases, the introduction of tumor-treating fields or targeted drugs on the basis of molecular markers of the tumor. These therapies collectively improve treatment outcomes, prolong survival, and support better quality of life.
Malignant Glioma Therapeutics Market- Market Dynamics
Growing Advancements In Medical Technology To Propel Market Demand
The growing advancements in medical technology are driving the Malignant Glioma Therapeutics market due to developments in the area of precision medicine, targeted treatments, immunotherapy, CAR-T cell therapy, genomic profiling, and artificial intelligence in the development of new treatments for glioma. For instance, in August 2025, according to the U.S. Department of Commerce, the size of the medical device market in Germany was valued at around USD 44,000 million (EUR 38,000 million) per year, representing 26.5 percent of the medical devices market in Europe. Being the third-largest market in the global medical technology market and the largest one in Europe. The contribution made by the healthcare sector in Germany towards gross value added was valued at USD 496,000 million (EUR 435,000 million), which was 11.5 percent of Germany’s gross value added. These technological advancements are accelerating the adoption of innovative and personalized glioma treatment approaches.
Malignant Glioma Therapeutics Market- Segmentation Analysis:
The Global Malignant Glioma Therapeutics market is segmented on the basis of Treatment, Drug Class, End Use, and Region.
Within the treatment segment in the Malignant Glioma Therapeutics market, surgery plays a crucial role because surgery is the major treatment approach that helps in the removal of the biggest tumor possible without putting the health of the patient at any risk, and the residual disease is managed through radiation therapy and chemotherapy, which includes temozolomide, lomustine, and carmustine wafers. For example, in January 2026, 5.01 million cataract surgeries were performed in the EU, and it has now become one of the most important types of surgery carried out in the EU. It has been followed by 1.11 transluminal coronary angioplasties; 1.10 million caesarean deliveries; 1.06 million hip replacements; and 931,000 inguinal hernias being repaired in the EU. This growing surgical demand supports continued adoption of advanced treatment approaches for malignant glioma patients.
Malignant Glioma Therapeutics Market- Geographical Insights
Geographically, the Malignant Glioma Therapeutics market is a result of such elements as healthcare facilities, disease prevalence, regulatory environments, and investments in research and development. North America holds a prominent position in the market because of high health care spending, the presence of pharmaceutical and biotech firms, research efforts, and advanced therapies. For instance, in January 2026, according to the U.S. Centers for Medicare & Medicaid Services (Gov), U.S. health care spending grew 7.2% to $5.3 trillion (USD), or $15,474 per person. \"Health care spending in the USA amounted to 18.0% of GDP, indicating a relatively high health care spending level in the country. These factors reinforce North America’s dominant position in the malignant glioma therapeutics market.
India Malignant Glioma Therapeutics Market - Country Insights
India’s market growth is driven by improving healthcare infrastructure, an increase in awareness among people about brain cancers, increased healthcare expenditure, and a growing patient population. For instance, in October 2025, according to the Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), the International Brain Tumor Awareness Week takes place every year from 25th Oct to 1st Nov with the objective of making people aware of the importance of raising awareness about brain tumors and their early detection & interventions, and also offering solace to the patients & attendants of the disease.” RGCIRC estimates that “there are more than 100 different types of brain tumors, which can occur in anyone & anywhere in the brain, irrespective of age; hence, awareness about the symptoms such as headache, seizures, vision changes, balance problems, and changes in speech and thinking abilities becomes imperative.\" This growing awareness is expected to support earlier diagnosis and strengthen demand for advanced brain cancer care in India.
Malignant Glioma Therapeutics Market- Competitive Landscape:
The competitive scenario in the Malignant Glioma Therapeutics market includes already existing pharmaceutical and biotech players working towards improving their treatment options by way of drug development and research & development. Some of the prominent players in the Malignant Glioma Therapeutics market are F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Merck & Co., Inc., Bristol-Myers Squibb Company, and Azurity Pharmaceuticals, Inc., who manage to maintain a significant market position through the development of innovative therapies and R&D activities. In May 2025, AstraZeneca’s experimental ATM kinase inhibitor AZD1390 was activated as one of the investigational arms of the GBM AGILE platform trial for newly diagnosed glioblastoma patients, which helps the company to develop targeted treatments for malignant glioma. These companies continue to advance malignant glioma treatment through innovative therapies, clinical development, and strategic collaborations.
Recent Developments:
- In October 2025, AbbVie’s ABBV-155 will be tested in a clinical trial along with radiotherapy for patients with glioblastoma, moving forward in the study of the targeted cancer drug from this pharmaceutical company.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Hoffmann-La Roche Ltd.
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
- Bristol Myers Squibb Company
- AstraZeneca plc
- Eli Lilly and Company
- Amgen Inc.
- Bayer AG
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Novocure
- Jazz Pharmaceuticals plc
- Amneal Pharmaceuticals, Inc.
- Karyopharm Therapeutics Inc.
- Sumitomo Pharma / Sumitomo Dainippon Pharma Oncology
- Genenta Science S.p.A.
- Others
GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET, BY TREATMENT- MARKET ANALYSIS, 2020 - 2033
- Chemotherapy
- Temozolomide
- Lomustine
- Carmustine Wafers
- Other
- Radiation Therapy
- Surgery
- Targeted Therapy (Bevacizumab)
- Tumor Treating Field (TTF) Therapy
GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- Alkylating Agents
- Anti-Angiogenic Agents
- Antineoplastic Antibiotics
- Targeted / Molecular Therapies
- Others
GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET, BY END USE- MARKET ANALYSIS, 2020 - 2033
- Hospitals
- Ambulatory Surgical Centers
- Clinics / Outpatient Centers
- Others
GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
TABLE OF CONTENTS
1. Malignant Glioma Therapeutics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Malignant Glioma Therapeutics Market Snippet by Treatment
2.1.2. Malignant Glioma Therapeutics Market Snippet by Drug Class
2.1.3. Malignant Glioma Therapeutics Market Snippet by End Use
2.1.4. Malignant Glioma Therapeutics Market Snippet by Country
2.1.5. Malignant Glioma Therapeutics Market Snippet by Region
2.2. Competitive Insights
3. Malignant Glioma Therapeutics Key Market Trends
3.1. Malignant Glioma Therapeutics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Malignant Glioma Therapeutics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Malignant Glioma Therapeutics Market Opportunities
3.4. Malignant Glioma Therapeutics Market Future Trends
4. Malignant Glioma Therapeutics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Malignant Glioma Therapeutics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Malignant Glioma Therapeutics Market Landscape
6.1. Malignant Glioma Therapeutics Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Malignant Glioma Therapeutics Market – By Treatment
7.1. Overview
7.1.1. Segment Share Analysis, By Treatment, 2025 & 2033 (%)
7.1.2. Chemotherapy
7.1.2.1. Temozolomide
7.1.2.2. Lomustine
7.1.2.3. Carmustine Wafers
7.1.2.4. Other
7.1.3. Radiation Therapy
7.1.4. Surgery
7.1.5. Targeted Therapy (Bevacizumab)
7.1.6. Tumor Treating Field (TTF) Therapy
8. Malignant Glioma Therapeutics Market – By Drug Class
8.1. Overview
8.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
8.1.2. Alkylating Agents
8.1.3. Anti-Angiogenic Agents
8.1.4. Antineoplastic Antibiotics
8.1.5. Targeted / Molecular Therapies
8.1.6. Others
9. Malignant Glioma Therapeutics Market – By End Use
9.1. Overview
9.1.1. Segment Share Analysis, By End Use, 2025 & 2033 (%)
9.1.2. Hospitals
9.1.3. Ambulatory Surgical Centers
9.1.4. Clinics / Outpatient Centers
9.1.5. Others
10. Malignant Glioma Therapeutics Market – By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
10.2. North America
10.2.1. Overview
10.2.2. Malignant Glioma Therapeutics Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.2.4. North America Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.2.5. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.2.6. North America Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Malignant Glioma Therapeutics Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.3.6. Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.8.3. UK Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.8.4. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.3.8.5. UK Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.9.3. France Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.9.4. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.3.9.5. France Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.10.3. Italy Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.10.4. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.3.10.5. Italy Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.11.3. Spain Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.11.4. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.3.11.5. Spain Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.12.3. The Netherlands Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.12.4. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.3.12.5. The Netherlands Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.3.13.5. Sweden Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.14.3. Russia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.14.4. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.3.14.5. Russia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.15.3. Poland Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.15.4. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.3.15.5. Poland Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.16. Denmark
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.16.3. Denmark Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.16.4. Denmark Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.3.16.5. Denmark Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.3.17. Rest of Europe
10.3.17.1. Overview
10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.3.17.5. Rest of the Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Malignant Glioma Therapeutics Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.4.4. APAC Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.5. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.4.6. APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.7.3. China Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.7.4. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.4.7.5. China Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.8.3. India Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.8.4. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.4.8.5. India Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.12.3. Indonesia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.12.4. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.4.12.5. Indonesia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.13.3. Thailand Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.13.4. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.4.13.5. Thailand Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.15. Taiwan
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.15.3. Taiwan Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.15.4. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.4.15.5. Taiwan Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.16. Vietnam
10.4.16.1. Overview
10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.16.3. Vietnam Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.16.4. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.4.16.5. Vietnam Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.4.17. Rest of APAC
10.4.17.1. Overview
10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.17.3. Rest of APAC Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.4.17.4. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.4.17.5. Rest of APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Malignant Glioma Therapeutics Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.5.4. LATAM Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.5.5. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.5.6. LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Malignant Glioma Therapeutics Key Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.6.4. MEA Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.5. MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.6.6. MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.8.3. UAE Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.8.4. UAE Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.6.8.5. UAE Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.13. Iran
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.13.3. Iran Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.13.4. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.6.13.5. Iran Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.14. Qatar
10.6.14.1. Overview
10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.14.3. Qatar Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.14.4. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.6.14.5. Qatar Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
10.6.15. Rest of MEA
10.6.15.1. Overview
10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.15.3. Rest of MEA Market Size and Forecast, By Treatment, 2020 - 2033 (US$ Million)
10.6.15.4. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
10.6.15.5. Rest of MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11. Key Vendor Analysis- Malignant Glioma Therapeutics Industry
11.1. Competitive Benchmarking
11.1.1. Competitive Dashboard
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. F. Hoffmann-La Roche Ltd.
11.2.2. Novartis AG
11.2.3. Merck & Co., Inc.
11.2.4. Pfizer Inc.
11.2.5. Bristol Myers Squibb Company
11.2.6. AstraZeneca plc
11.2.7. Eli Lilly and Company
11.2.8. Amgen Inc.
11.2.9. Bayer AG
11.2.10. AbbVie Inc.
11.2.11. Teva Pharmaceutical Industries Ltd.
11.2.12. Sun Pharmaceutical Industries Ltd.
11.2.13. Novocure
11.2.14. Jazz Pharmaceuticals plc
11.2.15. Amneal Pharmaceuticals, Inc.
11.2.16. Karyopharm Therapeutics Inc.
11.2.17. Sumitomo Pharma / Sumitomo Dainippon Pharma Oncology
11.2.18. Genenta Science S.p.A.
11.2.19. Others
12. 360 Degree AnalystView
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Hoffmann-La Roche Ltd.
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
- Bristol Myers Squibb Company
- AstraZeneca plc
- Eli Lilly and Company
- Amgen Inc.
- Bayer AG
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Novocure
- Jazz Pharmaceuticals plc
- Amneal Pharmaceuticals, Inc.
- Karyopharm Therapeutics Inc.
- Sumitomo Pharma / Sumitomo Dainippon Pharma Oncology
- Genenta Science S.p.A.
- Others
GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET, BY TREATMENT- MARKET ANALYSIS, 2020 - 2033
- Chemotherapy
- Temozolomide
- Lomustine
- Carmustine Wafers
- Other
- Radiation Therapy
- Surgery
- Targeted Therapy (Bevacizumab)
- Tumor Treating Field (TTF) Therapy
GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- Alkylating Agents
- Anti-Angiogenic Agents
- Antineoplastic Antibiotics
- Targeted / Molecular Therapies
- Others
GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET, BY END USE- MARKET ANALYSIS, 2020 - 2033
- Hospitals
- Ambulatory Surgical Centers
- Clinics / Outpatient Centers
- Others
GLOBAL MALIGNANT GLIOMA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
